Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
Feature|Articles|May 15, 2026
TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).
Advertisement
Advertisement
Linda Carpenter, MD, professor of psychiatry and human behavior at Brown University, used to arrive at the clinic early to deliver transcranial magnetic stimulation (TMS). If a patient couldn’t make it at the 8 am opening time, she and her colleagues would come at 7:30 am. If a patient could only do 6 pm, Carpenter would stay late for 3 months straight.
Related to this article
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Advertisement
Advertisement